A phase II clinical trial of HTL18318 for the treatment of cognitive impairment in patients with dementia with Lewy bodies
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs HTL 18318 (Primary)
- Indications Cognition disorders; Lewy body disease
- Focus Therapeutic Use
- 09 Nov 2017 According to a Sosei media release, this trial is expected to begin in 2018.
- 15 Feb 2016 New trial record
- 10 Feb 2016 This trial is expected to begin in late 2016, according to a Sosei Group Corporation media release.